An observational hospital based study to compare hemoglobin level among cancer patients

Munish Kumar Sharma¹, Neeraj Gour²*, Awadhesh Pandey³, Dhiraj Srivastava⁴

INTRODUCTION

Cancer related anemia (CRA) is a major healthcare problem. As many as three-fourths of cancer patients have anemia at some time during their illness (66% for solid tumors and 72% for hematological malignancies), 40% of them (36% of solid tumors and 47% of hematological malignancies) being severe enough to warrant red blood cell (RBC) transfusions.¹ In the Indian context, these figures are likely to be higher due to the prevailing malnutrition in the general population.²⁻⁴ It also varies with the underlying type of cancer, being highest for lung and ovarian cancer.⁷ Factors that predict development of CRA include advancing age, baseline Hb levels, transfusions in the past 6 months and myelosuppressive therapy (chemotherapy or radiation therapy).⁹

There is a general consensus that Hb levels below 8 g/dl are considered severe. There is a growing body of evidence that both functional status and QoL are significantly compromised in cancer patients with hemoglobin (Hb) values equal or less than 12 g/dL. Moderately anemic cancer patients (Hb, 8–10 g/dL) exhibit fatigue, lethargy, dyspnea, loss of appetite and inability to concentrate, affecting their overall QoL (quality of life).⁷

ABSTRACT

Background: Cancer related anemia (CRA) is a major healthcare problem. In the Indian context, these figures are likely to be higher due to the prevailing malnutrition in the general population. We have conducted this observational hospital based study on cancer patients with following objectives: 1) to assess the socio demographic profile of different cancer patients admitted at hospital; 2) to measure hemoglobin level among different cancer patients admitted at hospital on the basis of socio demographic profile and type of cancer.

Methods: The registers maintained in the department of Radiotherapy were checked and those belonging to the year 2011-12 were utilized to analyze the cancer patient’s data in respect to age, type of cancer, hemoglobin level admitted in health care facility.

Results: As far as distribution of Hb level is concerned among all cancer patients, 87.56% patients were having Hb level more than 9gm% and around 12.43% patients were having Hb level less than 9 gm%. Majority of patients whose Hb level was less than 9gm% were belonging to age group more than 45 years.

Conclusions: It is very much evident that anemia among cancer patients is a major healthcare problem and should be taken seriously.

Keywords: Hemoglobin, Cancer patients
Detection of anemia among cancer patients and an early intervention may have impact on their quality of life (QoL) and overall survival. We have conducted this observational hospital based study on cancer patients with following objectives:

1. To assess the socio demographic profile of different cancer patients admitted at hospital.
2. To measure hemoglobin level among different cancer patients admitted at hospital on the basis of socio demographic profile & type of cancer.

**METHODS**

As a part of training, the undergraduate medical students are supposed to visit the Medical Record Department (MRD) of Government Medical College Hospital (GMCH), sector-32, Chandigarh which is barely 18 years old. Supervision of MBBS student’s visit to MRD of GMCH, made us to know that disease-wise record of patients is not maintained there. Being adjacent to us, the department of Radiotherapy was visited many times during OPD hours. The faculty members were contacted and permission was obtained from them to take help of registers for analyzing data on cancer patient’s profile.

Inclusion and exclusion criteria

Records of cancer patients pertaining to year 2011 to 2012 were included in the study. Rest all records were excluded from the study.

Percentages were calculated to obviate the confounding effects of change in total number of patients. EpiCalc 2000 software was used for statistical analysis of data.

**RESULTS**

This study has collected data of 981 cancer patients over the time of year 2011-12. Out of these patients majority of patients were of breast cancer (31%) and cervical cancer (31.19%) followed by patients of other cancer. Among patients of breast cancer and cervical cancer majority of patients were in the age group of 45-59 years (Table 1).

| Age group (in yrs) | Lung, tongue, larynx, pharynx N (%) | Breast N (%) | Cervix N (%) | Upper GIT N (%) | Lower GIT N (%) | Others N (%) |
|-------------------|-------------------------------------|--------------|--------------|----------------|----------------|--------------|
| <30               | 04 (4.3)                            | 11 (3.5)     | 06 (1.96)    | 01 (09.7)      | 02 (4.5)       | 26 (20.47)   |
| 30-44             | 12 (13.18)                          | 79 (25.48)   | 74 (24.18)   | 24 (23.30)     | 05 (11.36)     | 29 (22.83)   |
| 45-59             | 44 (48.35)                          | 160 (51.61)  | 134 (43.79)  | 43 (41.74)     | 12 (27.27)     | 21 (16.53)   |
| 60+               | 31 (34.06)                          | 60 (19.35)   | 92 (30.06)   | 35 (33.98)     | 25 (56.81)     | 51 (40.15)   |
| All ages          | 91 (100)                            | 310 (100)    | 306 (100)    | 103 (100)      | 44 (100)       | 127 (100)    |

Organ distribution of cancer from total (%) n/N

| Total cancer patients (N)=981. |

| Table 1: Distribution of cancer patients on the basis of age groups and organ affected. |

| Age group (in yrs) | Lung, tongue, larynx, pharynx (Hb gm%) | Breast (Hb gm%) | Cervix (Hb gm%) | Upper GIT (Hb gm%) | Lower GIT (Hb gm%) | Others (Hb gm%) |
|-------------------|----------------------------------------|-----------------|-----------------|--------------------|--------------------|-----------------|
| <9                | >9                                     | <9              | >9              | <9                 | >9                 | <9              |
| <30               | 0 (00)                                 | 4(4.8)          | 0 (00)          | 11 (3.7)           | 5 (2.04)           | 1 (0.01)        |
| 30-44             | 3 (37.5)                               | 9 (10.84)       | 1 (7.14)        | 78 (26.35)         | 19 (30.64)         | 55 (22.54)      |
| 45-59             | 4 (50)                                 | 40 (48.19)      | 9 (64.28)       | 151 (51.01)        | 21 (33.87)         | 71 (22.54)      |
| 60+               | 1 (12.5)                               | 30 (36.14)      | 4 (28.57)       | 56 (18.91)         | 21 (33.87)         | 71 (29.09)      |
| All ages          | 8 (100)                                | 83 (100)        | 14 (100)        | 296 (100)          | 62 (100)           | 244 (100)       |

| Organ wise distribution of Hb from total (%) n/N |
|--------------------------------------------------|
| Total cancer patients (N)=981.                   |

| Table 2: Distributions of cancer patients on the basis of age groups and hemoglobin level in blood. |

| Age group (in yrs) | Lung, tongue, larynx, pharynx (Hb gm%) | Breast (Hb gm%) | Cervix (Hb gm%) | Upper GIT (Hb gm%) | Lower GIT (Hb gm%) | Others (Hb gm%) |
|-------------------|----------------------------------------|-----------------|-----------------|--------------------|--------------------|-----------------|
| <9                | >9                                     | <9              | >9              | <9                 | >9                 | <9              |
| <30               | 0 (00)                                 | 4(4.8)          | 0 (00)          | 11 (3.7)           | 5 (2.04)           | 1 (0.01)        |
| 30-44             | 3 (37.5)                               | 9 (10.84)       | 1 (7.14)        | 78 (26.35)         | 19 (30.64)         | 55 (22.54)      |
| 45-59             | 4 (50)                                 | 40 (48.19)      | 9 (64.28)       | 151 (51.01)        | 21 (33.87)         | 71 (22.54)      |
| 60+               | 1 (12.5)                               | 30 (36.14)      | 4 (28.57)       | 56 (18.91)         | 21 (33.87)         | 71 (29.09)      |
| All ages          | 8 (100)                                | 83 (100)        | 14 (100)        | 296 (100)          | 62 (100)           | 244 (100)       |

| Organ wise distribution of Hb from total (%) n/N |
|--------------------------------------------------|
| Total cancer patients (N)=981.                   |
As far as distribution of Hb level is concerned among all cancer patients, 87.56% patients were having Hb level more than 9 gm% and around 12.43% patients were having Hb level less than 9 gm%. Majority of patients whose Hb level was less than 9gm% were belonging to age group more than 45 years (p<0.01) (Table 2).

This study has collected data of 981 cancer patients over the time of year 2011-12. Out of these patients majority of patients were of breast cancer (31%) and cervical cancer (31.19%) followed by patients of other cancer. Out of total cancer patients of different parts of body cervical cancer (6.3%) patients were having hemoglobin level less than 9 gm% followed by other cancers. Majority of cancer patients were having hemoglobin level more than 9 gm% (Table 2).

As far as distribution of Hb level is concerned among all cancer patients, while a study conducted in Italy and Austria with 1136 solid tumor patients showed an overall anemia prevalence of 31%.9,10 However, a study of solid tumor patients presenting at Belgian oncology and hematology centers found a lower prevalence of 13.8%.11 The Australian Cancer Anemia Survey conducted during the same time as the ECAS showed a 35% anemia prevalence in cancer patients at the time of enrollment.12 A single centre retrospective study in 148 patients with solid tumors in Japan reported that 44% had anemia at enrollment.13

Iron profile monitoring is recommended. Iron replacement is recommended if there is iron deficiency, but there is not enough evidence for greater details regarding the form of replacement and periodicity of monitoring.14 Iron replacements should be restricted to patients with absolute or functional iron deficiency.15

Hospital based study with small sample size were few of the limitations of this study. Nevertheless this study adds in to previously available literature on anemia among cancer patients and warrants more studies to be conducted on this major health issue among ailing cancer patients.

CONCLUSION

It is very much evident that anemia among cancer patients is a major healthcare problem and should be taken seriously. Its causes are well established and already reported in literature of repute. It impacts over all QoL (quality of life) more than is perceived by doctors. If not treated, it can shorten survival as well. What are the different guidelines existed for management of such patients should be explored. This small study was merely an attempt to surface this important health issue among cancer patients and to contribute in previously available literature in a bid to end up with more conclusive and acceptable evidence.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European
Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293-306.

2. Parikh PM, Bakshi A. Cancer related Anemia - Guidelines for Developing Countries. Mumbai, India: Elsevier; 2004.

3. Bahl A, Sharma DA, Basu J, Rath GK, Julka PK. Pretreatment anemia evaluation in cancer patients attending radiotherapy clinic: Results from a single Indian center. Indian J Med Sci. 2008;62:417-20.

4. The National Family Health Survey (NFHS-3) of India of 2005-06. Available at: http://www.nfhsindia.org/nfhs3.shtml. Accessed on 3 August 2017.

5. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst. 1999;9:1616-34.

6. Cella D. Quality of life and clinical decisions in chemotherapy induced anemia. Oncology. 2006;20:25-8.

7. Kanuri G, Sawhney R, Varghese J, Britto M, Shet A. Iron Deficiency Anemia Coexists with Cancer Related Anemia and Adversely Impacts Quality of Life. PLoS ONE. 2016;11(9):e0163817.

8. Naoum FA. Iron deficiency in cancer patients. rev bras hematol hemoter. 2016;38(4):325–30.

9. Steegmann JL, Sanchez Torres JM, Colomer R, Vaz A, Lopez J, Jalon I, et al. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2013;15(6):477-83.

10. Merlini L, Carteni G, Iacobelli S, Stelitano C, Airoldi M, Balcke P, et al. Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy. Cancer management and research. 2013;5:205-14.

11. Verbeke N, Beguin Y, Wildiers H, Canon JL, Bries G, Bosly A, et al. High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008). Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2012;20(1):23-8.

12. Sheshadri T, Prince HM, Bell DR, Coughlin PB, James PP, Richardson GE, et al. The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer. Med J Australia. 2005;182(9):453-7.

13. Kitano T, Tada H, Nishimura T, Teramukai S, Kanai M, Nishimura T, et al. Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy. Int J Hematol. 2007;86(1):37-41.

14. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Hematology/AmericanSociety of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045–59.

15. Aapro MS, Link H. September 2007 update on EORTC guidelines and anaemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13(3):33–6.

Cite this article as: Sharma MK, Gour N, Pandey A, Srivastava D. An observational hospital based study to compare haemoglobin level among cancer patients. Int J Community Med Public Health 2018;5:361-4.